Product Description
KW-2450 is an oral dual insulin-like growth factor-1 receptor/insulin receptor tyrosine kinase inhibitor.
Mechanisms of Action: IGF Inhibitor, INSR Inhibitor
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: N/A
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Company: Kyowa Kirin Co., Ltd.
Company Location:
Company Founding Year: None
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 1: Oncology Solid Tumor Unspecified|Breast Cancer
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT01199367 |
2450-US-002 | P1 |
Terminated |
Breast Cancer |
2012-12-01 |
2024-04-26 |
Primary Endpoints|Treatments |
|
NCT00921336 |
2450-US-001 | P1 |
Completed |
Oncology Solid Tumor Unspecified |
2010-08-01 |
2024-04-26 |
Recent News Events
Date |
Type |
Title |
|---|